A new £20 million project in Cambridge aims to transform drug testing by growing miniature human organs from NHS patients’ cells. This initiative seeks to improve the accuracy of medicine testing while significantly reducing the reliance on animal models, which have historically been inadequate for predicting human responses to drugs.
Researchers will create organoids—tiny clumps of human tissue—that can mimic the functions of full-sized organs. This shift is crucial as over 90% of drugs that pass animal testing fail in human trials, raising questions about the validity of such tests. The new organoid models promise to provide insights into how diseases manifest differently in individuals, allowing for more personalised treatment approaches.
The project aligns with government strategies to fast-track the reduction of animal testing through innovative methodologies. By developing a library of validated organoids, researchers hope to provide essential tools for both academia and the pharmaceutical industry, ultimately leading to safer and more effective drugs.
As scientists begin with organoids for conditions like inflammatory bowel diseases and cancer, the implications for future drug development are profound. This approach not only aims to enhance the efficacy of treatments but also to pave the way for a more ethical framework in medical research, reducing the number of animals used in testing.
Source: The Guardian
